Urology Times Journal, Jason M. Broderick - April 15, 2021 The PSMA-targeted radiopharmaceutical ¹⁷⁷Lu-PSMA-617 (LuPSMA) is rapidly advancing through the pipeline in metastatic castration-resistant prostate cancer (mCRPC), which is believed to become one of the first PSMA theranostics approved by the FDA. Scott T. Tagawa, MD, explained. Read the article >>